NewsFrequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Patients Receiving FX-322
NewsNew FX-322 clinical trial for severe hearing loss includes tinnitus assessment as secondary outcome measure
NewsFrequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss
NewsFrequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322
NewsCarl LeBel (Chief Development Officer at Frequency Therapeutics) talks FX-322 in latest interview – via Tinnitus Talk [PDF]
NewsFrequency Therapeutics Shares Clinical Data From Exploratory Study Confirming Delivery of FX-322 to the Cochlea – Top-Line Results Show Consistent Drug Entry in All Patients
NewsNO COVID-19 SLOWDOWN: Frequency Therapeutics Adds Another Recruitment Site for FX-322 Phase 2a Study (HearingLossTreatmentReport.com)
NewsFrequency Therapeutics CEO: “We have opened all U.S. sites for our Phase 2a study of FX-322 and remain on track to report top-line data in the second half of next year.”
NewsFrequency Therapeutics Begins Recruiting for Phase 2 Study of FX-322 in Patients with Sensorineural Hearing Loss
NewsFrequency Therapeutics prepares to advance first-in-class drug candidate FX-322 into Phase 2a study…
NewsFrequency Therapeutics licenses FX-322 outside U.S. to Astellas Pharma for $80M. Both companies will work on global clinical trials for the treatment and coordinate launch efforts.
NewsUPDATE: Frequency Therapeutics to present newest FX-322 clinical trial results on September 17, 2019 [early]
NewsFrequency Therapeutics to present major FX-322 update on September 18, 2019 at AAO-HNSF Annual Meeting in New Orleans
NewsFrequency Therapeutics plans on asking the FDA to fast track FX-322, citing recent studies that link hearing loss to other diseases like depression and dementia
NewsFrequency Therapeutics Completes Enrollment in Single Dose Safety Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration
NewsCould this new jab mean the end of hearing aids? Experimental treatment injected into the ear could restore hearing by growing new ‘hair’ cells
NewsFrequency Therapeutics’ First-in-Human Safety Study of FX-322 for Hearing Restoration Achieves All Endpoints
